GRI Bio, Inc. Common Stock (GRI) is a publicly traded Healthcare sector company. As of September 28, 2026, GRI trades at $2.06 with a market cap of $4.48M and a P/E ratio of -0.02. GRI moved +0.00% today. Year to date, GRI is -70.33%; over the trailing twelve months it is -96.21%. Its 52-week range spans $1.36 to $311.36. Analyst consensus is buy with an average price target of $27.00. Rallies surfaces GRI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GRI Bio executives present at 10th IPF Summit on immune modulation, Phase 2a IPF data: GRI Bio executives will present at the 10th IPF Summit in Boston from Sept. 29 to Oct. 1, 2026. CEO Marc Hertz is scheduled to discuss Phase 2a development insights for the company’s IPF program.
| Metric | Value |
|---|---|
| Price | $2.06 |
| Market Cap | $4.48M |
| P/E Ratio | -0.02 |
| EPS | $-121.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $311.36 |
| 52-Week Low | $1.36 |
| Volume | 7.95K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-11.96M |
| Gross Margin | 0.00% |
1 analysts cover GRI: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $27.00.